[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 22, 1985

Danazol and Hemophilia

Author Affiliations

University of Colorado Health Sciences Center Denver

JAMA. 1985;253(8):1167. doi:10.1001/jama.1985.03350320091025
Abstract

Danazol is a 2,3-isoxazol derivative of 17 α-ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, α1-antitrypsin, and Cl esterase inhibitor.1,2 Last year Gralnick and Rick1 reported evidence that danazol was associated with increased levels of factor VIIIc and factor IX and decreased transfusion requirements in patients with hemophilia. Subsequent studies by Gralnick and associates4 as well as other studies by Garewal et al5 are reported in this issue of The Journal and form the basis for this commentary.

The readers of the aforementioned articles are faced with a dilemma in judging the usefulness of danazol in management of hemophilia patients. Gralnick et al report on three of their initial patients plus eight French patients with hemophilia A.

×